|
| |
GE Healthcare introduces new Biacore
T100 software
Enables improved protein
characterization through calibration-free protein concentration analysis
UPPSALA, SWEDEN, 25 MARCH 2008 – GE Healthcare announced today that it is
introducing Biacore T100 software version 2, protein characterization software
for the Biacore T100 label-free protein interaction analysis system, to enable
calibration-free concentration analysis (CFCA) of proteins. For the first time
it will be possible to measure protein concentration without the need for a
standard.
The new software also comprises key functionality for protein characterization
that reduces time spent on development of kinetic analysis assays through the
single-cycle kinetics function. Single-cycle kinetics enables the analysis of
molecular interactions which have previously been difficult to determine. In
addition, data evaluation is significantly improved in the new software version
and enables multiple samples to be analysed together with a few simple clicks,
supported by inbuilt QC functions/tools.
Knowing the accurate concentration that relates to the specific binding activity
of a protein is key for many applications. Determination of the target-binding
drug fraction is extremely important during the development of therapeutic
proteins and provides a highly informative characterization profile in quality
control of biotherapeutics.
Resistentia Pharmaceuticals AB in Uppsala, Sweden, is developing
immunotherapeutic products for allergic asthma and inflammatory disorders. The
Company has developed a quantitative assay incorporating the Biacore T100 CFCA
methodology for quantification of a therapeutic protein during development, and
for implementation as a Quality Control assay at a CRO.
“Knowing the accurate concentration of a drug in early development and being
able to relate this to specific binding activity is invaluable in the design and
conduct of pre-clinical and clinical studies. Measurement of specific binding
activity raises the possibility of optimizing the production process of most
biologicals and thereby increasing the proportion of active drug resulting in
reduced COGS. In addition, the safety of a biological drug product may be
improved by reducing the amount of inactive substance” said Stefan Persson, VP
Toxicology, Resistentia. “The assay is not only fast and reliable but also means
that we don’t need to depend on the performance of standards, and the sample
consumption is very low so the need for scaling up of drug is minimized.”
The Biacore T100 is used throughout the drug discovery and development process,
from early research to QC. There are currently several hundreds of units
installed worldwide, in labs ranging from major pharmaceutical companies to
academic research institutes.
The new Biacore T100 software will be available from April 2008.
For more information please visit:
www.biacore.com
- ENDS -
Contact
College Hill
Katie Odgaard, Dr Marc Egelhofer, Rebecca Walker
+44 (0)20 7457 2020
ge-biacore@collegehill.com
| |
|
